Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 9/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24142877 | 0.88 | NR1D1 (0.49) | NR1D1ICMT | |
| SCHEMBL24143308 | 0.82 | NR1D1 (0.63) | NR1D1KCNH2DYRK1AAAK1ICMT | |
| SCHEMBL24142979 | 0.81 | NR1D1 (0.67) | NR1D1KCNH2DYRK1AICMT | |
| SCHEMBL24143419 | 0.80 | NR1D1 (0.69) | NR1D1KCNH2DYRK1A | |
| SCHEMBL24143668 | 0.79 | NR1D1 (0.53) | NR1D1KCNH2DYRK1AAAK1ICMT | |
| SCHEMBL24143622 | 0.79 | NR1D1 (0.64) | NR1D1KCNH2DYRK1AICMT | |
| SCHEMBL24143425 | 0.79 | NR1D1 (0.67) | NR1D1KCNH2DYRK1AICMT | |
| SCHEMBL24144496 | 0.78 | NR1D1 (0.61) | NR1D1KCNH2DYRK1AAAK1ICMT | |
| SCHEMBL24143422 | 0.78 | NR1D1 (0.63) | NR1D1KCNH2DYRK1AAAK1ICMT | |
| SCHEMBL26673768 | 0.77 | NR1D1 (0.49) | NR1D1KCNH2DYRK1AAAK1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2021263278-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339886-A1 | REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS | NR1H2, NR1H3, NR1D1 | NR1D1 3/4885KCNH2 4644/4885DYRK1A 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.